Sparano JA

ORCID: 0000-0002-9031-2010 · 1 paper in corpus

2014

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Journal of Clinical Oncology ·doi:10.1200/jco.2014.55.6993

PurposeThe effects of ovarian function suppression (OFS) on survival and patient-reported outcomes were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen with or without OFS.Patients and methods…